Once-daily ciclesonide in children: Efficacy and safety in asthma

Journal of Pediatrics

Volumn 148, Issue 3, 2006, Pages 377-383

  Gelfand, Erwin W ^a,b,c   Georgitis, John W ^a,b,c   Noonan, Michael ^a,b,c   Ruff, Michael E ^a,b,c  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b Respiratory Trials PLLC   (United States)

^c Dallas Allergy & Asthma Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CICLESONIDE; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; HYDROCORTISONE; PLACEBO; SALBUTAMOL; BRONCHODILATING AGENT; CORTICOSTEROID; PREGNANE DERIVATIVE;

ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; GLAUCOMA; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SORE THROAT; SUBCAPSULAR CATARACT; THRUSH; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; METERED DOSE INHALER; MULTICENTER STUDY; PRESCHOOL CHILD; QUALITY OF LIFE; TREATMENT OUTCOME; URINE;

ADRENAL CORTEX HORMONES; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROCORTISONE; METERED DOSE INHALERS; PREGNENEDIONES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33646176778     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2005.10.028     Document Type: Article

References (35)

1. National Institutes of Health, National Heart Lung and Blood Institute. National Asthma Education Program Expert Panel Report: guidelines for the diagnosis and management of asthma. NIH Publication 97-4051; 1997.
2. National Institutes of Health, National Heart Lung and Blood Institute. National Asthma Education and Prevention Program. Expert Panel report: Guidelines for the diagnosis and management of asthma, update on selected topics-2002. J Allergy Clin Immunol 110 (2002) S141-29
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung and Blood Institute NHLBI/WHO Workshop Report 2002. NIH Publication 02-3659; 2002.
4. Simons F.E. Benefits and risks of inhaled glucocorticoids in children with persistent asthma. J Allergy Clin Immunol 102 (1998) S77-S84
5. Allen D.B. Safety of inhaled corticosteroids in children. Pediatr Pulmonol 33 (2002) 208-220
6. Patrick D.L., and Deyo R.A. Generic and disease-specific measures in assessing health status and quality of life. Med Care 27 (1989) S217-S232
7. Lipworth B. Systemic adverse effects of inhaled corticosteroid therapy. a systemic review and meta-analysis. Arch Intern Med 159 (1999) 941-955
8. Toogood J.H. Side effects of inhaled corticosteroids. J Allergy Clin Immunol 102 (1998) 705-713
9. Cochrane G.M. Compliance and outcomes in patients with asthma. Drugs 52 (1996) 12-19
10. Dietzel K., Engelstatter R., and Keller A. Ciclesonide. An on-site activated steroid. Prog Respir Res 31 (2001) 91-93
11. Nave R., Meyer W., Fuhst R., and Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4 weeks inhalation of ciclesonide. Pulm Pharmacol Ther 18 (2005) 390-396
12. Bethke T. High lung deposition of ciclesonide in 2D and 3D imaging. Eur Respir J 20 (2002) S109
13. Rohatagi S., Zech K., and Banerji D. The lung deposition of HFA-formulation corticosteroids. a comparison of ciclesonide to other inhaled corticosteroids [abstract]. Ann Allergy Asthma Immunol 90 (2003) A129
14. Rohatagi S., Arya V., Zech K., Nave R., Hochhaus G., Jensen B.K., et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43 (2003) 365-378
15. Drollmann A., Hasselquist B., Boudreau R., et al. Ciclesonide shows high lung deposition in 2D and 3D imaging [abstract]. Am J Respir Crit Care Med 165 (2002) A188
16. Biberger C. Efficacy and safety of ciclesonide compared with budesonide in asthma patients. a randomized 12-week study [abstract]. Am J Respir Crit Care Med 167 (2003) A771
17. Lipworth B., Kaliner M., LaForce C., Baker J., Kaiser H., Amin D., et al. Effect of ciclesonide and fluticasone propionate on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 94 (2005) 465-472
18. Timmer W., Weinbrenner A., Hueneke D., Zschiesche M., Engel G., Wurst W., et al. Repeated inhalation of the new topical steroid ciclesonide does not lead to adrenal suppression in healthy subjects. [abstract]. Am J Resp Crit Care Med 161 (2000) A776
19. Postma D.S., Sevette C., Martinat Y., Schlosser N., Aumann J., and Kafe H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 17 (2001) 1083-1088
20. Szefler S., Rohatagi S., Williams J., Lloyd M., Kundu S., and Banerji D. Ciclesonide, a novel inhaled steroid, does not affect HPA-axis function in patients with moderate-to-severe persistent asthma. Chest 128 (2005) 1104-1114
21. Weinbrenner A., Huneke D., Zschiesche M., Engel G., Timmer W., Steinijans V.W., et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 87 (2002) 2160-2163
22. Juniper E.F., Guyatt G.H., Feeny D.H., Ferrie P.J., Griffith L.E., and Townsend M. Measuring quality of life in children with asthma. Qual Life Res 5 (1996) 35-46
23. Ringdal N., Lundback B., Alton M., Rak S., Eivindson A., Bratten G., et al. Comparable effects of inhaled fluticasone propionate and budesonide on the HPA-axis in adult asthmatic patients. Respir Med 94 (2000) 482-489
24. Casale T.B., Nelson H.S., Stricker W.E., Raff H., and Newman K.B. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 87 (2001) 379-385
25. Kristjansson S., Strannegard I.L., and Wennergren G. Inflammatory markers in childhood asthma. Ann Med 28 (1996) 395-399
26. Pedersen S., Garcia M.G., Manjra A., Vermeulen J., Theron I., and Engelstaetter R. Ciclesonide is as effective as fluticasone propionate in the treatment of children with persistent asthma. Allergy 113 (2004) S921
27. Pearlman D., Creticos P., Lampl K., Gower R., Kundu S., Fish J., et al. Once-daily ciclesonide is effective and well-tolerated in adult and adolescent patients with mild-to-moderate asthma. J Allergy Clin Immunol 116 (2005) 1206-1212
28. Richter K., Kanniess F., Biberger C., Nave R., and Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 45 (2005) 146-152
29. Bisgaard H., Allen D., Milanowski J., Kalev I., Willits L., and Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 113 (2004) e87-e94
30. Cumming R.G., and Mitchell P. Inhaled corticosteroids and cataract. prevalence, prevention and management. Drug Saf 20 (1999) 77-84
31. Pedersen S., and O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 52 (1997) 1-34
32. Agertoft L., and Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 115 (2005) 940-945
33. Barnes P.J. Current therapies for asthma. promise and limitations. Chest 111 (1997) 17S-26S
34. Haahtela T., Jarvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 331 (1994) 700-705
35. Campbell L. Once-daily inhaled corticosteroids in mild to moderate asthma. improving acceptance of treatment. Drugs 58 (1999) 25-33